Konruns(SH:603590) Xin Lang Cai Jing·2025-08-28 10:38Core Insights - 康辰药业 reported a total revenue of 461 million yuan for the first half of 2025, an increase of 55.84 million yuan compared to the same period last year, representing a year-on-year growth of 13.79% [1] - The net profit attributable to shareholders was 91.05 million yuan, ranking 14th among disclosed peers, with a year-on-year increase of 11.84 million yuan, reflecting a growth of 14.95% [1] - The company experienced a net cash outflow from operating activities of 1.17 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stands at 12.04%, ranking 15th among disclosed peers, a decrease of 0.17 percentage points from the same period last year [3] - The gross profit margin is reported at 90.18%, ranking 6th among peers, with a quarterly increase of 0.04 percentage points and a year-on-year increase of 0.65 percentage points, marking three consecutive years of growth [3] - The return on equity (ROE) is 2.92%, ranking 18th among peers, with a year-on-year increase of 0.38 percentage points [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.58 yuan, ranking 6th among peers, with an increase of 0.08 yuan year-on-year, reflecting a growth of 16.00% [3] - The total asset turnover ratio is 0.12 times, ranking 19th among peers, with a year-on-year increase of 0.01 times, representing a growth of 12.35% [3] - The inventory turnover ratio is 0.64 times, ranking 10th among peers [3] Shareholder Structure - The number of shareholders is 9,970, with the top ten shareholders holding a total of 89.32 million shares, accounting for 56.05% of the total share capital [3] - The largest shareholder, Liu Jianhua, holds 31.87% of the shares [3]